What Can You Expect in 2026?
Radiopharmaceuticals are transforming oncology, driven by breakthrough clinical results, expanding isotope portfolios, and strategic industry investments. With the radioligand therapy market projected to surpass $13 billion by 2032, the field is moving rapidly from experimental to mainstream, and theranostics are emerging as a cornerstone of precision medicine.
The 5th Targeted Radiopharmaceuticals Summit US brings together the full spectrum of the RLT ecosystem, offering an end-to-end view of radiopharmaceutical development, from discovery and preclinical research to clinical translation and commercialization. Across four tracks, featuring 58+ expert speakers and 260+ attendees, the summit provides a platform for sharing case studies, technical insights, and practical solutions to the challenges shaping the field today.
Key topics this year include:
- Optimizing dosimetry and clinical trial design to meet FDA guidance and accelerate patient access
- Combining diagnostics and therapeutics to deliver truly personalized oncology treatments
- Scaling isotope production, addressing global supply challenges, and implementing automation for reproducible workflows
- Innovating in radiochemistry with novel isotopes, chelator design, and drug optimization strategies
- Strengthening CDMO partnerships, managing short half-life logistics, and ensuring GMP‑compliant manufacturing and supply chains
This summit is designed for everyone in the radiopharmaceutical ecosystem - researchers, clinicians, drug developers, and industry leaders - offering the insights, connections, and strategies needed to advance radioligand therapies from concept to clinic. Whether your focus is target discovery, translational development, or commercial-scale production, the 5th TRP Summit US is the place to explore solutions, exchange ideas, and shape the future of precision oncology.
Unmissable Event Highlights
Harness emerging alpha emitters like At-211 and Pb-212 to deliver potent tumor cytotoxicity while addressing off-target risks and overcoming production and logistical hurdles
Combine radioligand therapy with DDR inhibitors, ADCs, and immunotherapies to amplify tumor kill, extend progression-free survival, and reduce dose-related toxicity.
Optimize tumor retention and minimize off-target exposure using advanced molecular design, proximity-induced covalent binding, biparatopic antibodies, and pretargeting strategies.
Translate preclinical insights into safer, faster clinical development through imaging-guided dosimetry, PK modeling, and advanced chelator-linker chemistry for confident Phase 0/1 dosing decisions.
Navigate supply chain and manufacturing bottlenecks for short half-life isotopes, scaling from preclinical production to commercial delivery while maintaining GMP compliance and reliability.
Build clinical, regulatory, and operational readiness to move therapies efficiently from discovery through Phase 2/3 and into commercial launch, ensuring patient access and long-term impact.
Divide & Conquer
Built with input from experts at Novartis, Eli Lilly, AstraZeneca, and many others, this years program has been specifically designed to address the key challenges at each stage of development, the Summit will also bring everyone together with broader topics covered in our plenary session, catering to the entire audience.
What is your Job Title?
- Radiochemist, Structural Biologist
- Discovery Scientist
- Medicinal Chemist
- Chief Scientific Officer
- Director – Targeting Technologies
- Director – Chemistry
- R&D Specialist
- Biologist
- Preclinical Scientist
- Head of Translational Medicine & Non Clinical Development
- Chief Executive Officer
- Director – Preclinical Development
- Clinician
- Clinical Scientist
- Translational Scientist
- Chief Medical Officer
- Director – Clinical Development
- Chief Executive Officer
- Analytical Scientist
- Procurement Specialist
- Supply Chain Executive
- Chief Executive Officer
- Vice President – CMC
- Director – Supply Chain
Explore the Full Event Guide
- 260+ Attendees from World-Leading RLT Companies
- 66+ Speakers including Novartis, AstraZeneca, RayzeBio & Convergent Therapeutics
- 8+ Hours of Dedicated Networking alongside pioneers in the RLT industry
- 4 Tracks of Content: An agenda built for your team, spanning from Discovery to
CMC & Supply Chain - 22+ C-Suite Speakers with direct influence on their companies’ pipelines & decision-making
Attending Companies Include
Explore the Agenda
Discover how leading scientists and clinicians in TRP and radioligand therapy are redefining every stage of development - from target discovery and validation to isotope selection and commercialization strategy. Gain insight into the approaches shaping the next generation of radiopharmaceutical therapies and accelerating their path to the clinic.
Partner With Us
Engage directly with key decision-makers across imaging, radiochemistry, isotope development and more, who are actively seeking collaborations. Explore opportunities to accelerate the development of safer, more effective radiopharmaceuticals and contribute to projects that move quickly from concept to clinical application.
Join TRP Experts
Network with over 260 radiochemists, biologists, clinicians, and R&D leaders who are shaping the full RLT pipeline. Share expertise, exchange ideas, and collaborate across discovery, preclinical development, and clinical translation to advance therapies that can make a real impact for patients.